Administer preinfusion medications. The recommended dose of SARCLISA is 10 mg/kg actual body weight administered as an IV infusion in combination with Pd.
Incremental escalation of the infusion rate should be considered only in the absence of IRRs.
SARCLISA should be administered by a healthcare professional, with immediate access to emergency equipment and appropriate medical support to manage IRRs if they occur.1
75-minute infusion time starting after the second infusion in the absence of IRRs1
Administer the following premedications prior to SARCLISA infusion to reduce the risk and severity of IRRs:
The above recommended dose of dexamethasone (orally or IV) corresponds to the total dose to be administered only once before infusion as part of the premedication and of the backbone treatment, before SARCLISA and pomalidomide administration.
Administer the recommended premedication agents 15 to 60 minutes prior to starting a SARCLISA infusion.
No post-treatment medications are required for SARCLISABack to top
Prepare the solution for infusion using an aseptic technique as follows:
No dose reduction of SARCLISA is recommended. Dose delay may be required to allow recovery of blood counts in the event of hematological toxicity. For information concerning drugs given in combination with SARCLISA, see manufacturer's Prescribing Information.
For other medicinal products that are administered with SARCLISA, refer to the respective current Prescribing Information.Back to top
SARCLISA injection is a clear to slightly opalescent, colorless to slightly yellow solution, essentially free of visible particulates, supplied as follows:
Discard unused portion of solution. All materials that have been utilized for dilution and administration should be disposed of according to standard procedures.
IRR=infusion-related reaction; IV=intravenous; NDC=National Drug Code; Pd=pomalidomide and dexamethasone.